Atlantis Health Care Group (Puerto Rico), Inc. is a medicare approved dialysis facility center in Guaynabo, Puerto Rico and it has 18 dialysis stations. It is located in Guaynabo county at Carr. 199 Ave Las Cumbres # 140, Guaynabo, PR, 00969. You can reach out to the office of Atlantis Health Care Group (Puerto Rico), Inc. at (787) 292-7979. This dialysis clinic is managed and/or owned by Atlantis Healthcare Group. Atlantis Health Care Group (Puerto Rico), Inc. has the following ownership type - Profit. It was first certified by medicare in July, 2003. The medicare id for this facility is 402534 and it accepts patients under medicare ESRD program.
| Name | Atlantis Health Care Group (Puerto Rico), Inc. |
|---|---|
| Location | Carr. 199 Ave Las Cumbres # 140, Guaynabo, Puerto Rico |
| No. of Dialysis Stations | 18 |
| Medicare ID | 402534 |
| Managed By | Atlantis Healthcare Group |
| Ownership Type | Profit |
| Late Shifts | No |
| Carr. 199 Ave Las Cumbres # 140, Guaynabo, Puerto Rico, 00969 | |
| (787) 292-7979 | |
| Not Available |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
| NPI Number | 1184831398 |
| Organization Name | Renal Center Of Guaynabo |
| Doing Business As | Atlantis Health Care Group Puerto Rico Inc |
| Address | Guaynabo Medical Mall # 140 Guaynabo, Puerto Rico, 00970 |
| Phone Number | (787) 292-7979 |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 39 |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 115 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1063 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Atlantis Health Care Group (Puerto Rico), Inc. with elevated calcium levels.
| Patients with hypercalcemia | 116 |
| Hypercalcemia patient months | 1071 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 118 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 49 |
| Patient months included in arterial venous fistula and catheter summaries | 460 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Given that phages are able to destroy bacteria, they are of particular interest to science. Basic researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin are especially interested in the tube used by phages to implant their DNA into bacteria.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
Researchers at Duke University have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease - Duchenne muscular dystrophy (DMD) - for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
› Verified 3 days ago